(Q40171974)

18 September 2017

title

Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells (English)

1 reference

18 September 2017

1

1 reference

18 September 2017

Antonella Naldini

6

0 references

Fabio Carraro

object named as

Fabio Carraro

9

0 references

Giovanni Maga

object named as

Giovanni Maga

8

1 reference

ORCID Public Data File 2021

Maurizio Botta

10

object named as

Maurizio Botta

1 reference

18 September 2017

Annalisa Pucci

2

1 reference

18 September 2017

Matteo Magnani

3

1 reference

18 September 2017

Giada A Locatelli

4

1 reference

18 September 2017

Chiara Brullo

5

1 reference

18 September 2017

Silvia Schenone

7

1 reference

18 September 2017

publication date

1 March 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

2

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

343-353

1 reference

Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

The second generation of BCR-ABL tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Overcoming drug resistance in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Targeted CML therapy: controlling drug resistance, seeking cure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Inhibitors of Bcr-abl... breaking new ground again

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Dual tyrosine kinase inhibitors in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Bcl-XL protects BimEL-induced Bax conformational change and cytochrome C release independent of interacting with Bax or BimEL.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Nonionic detergents induce dimerization among members of the Bcl-2 family

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Development and validation of a genetic algorithm for flexible docking

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Improved protein-ligand docking using GOLD

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600214

7 January 2021

Identifiers

DOI

10.1002/CMDC.200600214

1 reference

18 September 2017

1 reference